LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Search

PTC Therapeutics Inc

Închisă

Sector Sănătate

40.41 1.43

Rezumat

Modificarea prețului

24h

Curent

Minim

40.14

Maxim

40.71

Indicatori cheie

By Trading Economics

Venit

-7.6M

-99M

Vânzări

-23M

187M

EPS

-1.29

Marjă de profit

-53.122

Angajați

988

EBITDA

-47M

-35M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+1.51 upside

Dividende

By Dow Jones

Următoarele câștiguri

7 nov. 2024

Statistici piață

By TradingEconomics

Capitalizare de piață

183M

3.1B

Deschiderea anterioară

38.98

Închiderea anterioară

40.41

Sentimentul știrilor

By Acuity

50%

50%

167 / 389 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

PTC Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

25 ian. 2024, 23:44 UTC

Acțiuni populare

Stocks to Watch: Intel, PTC Therapeutics, KLA

Comparație

Modificare preț

PTC Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

1.51% sus

Prognoză pe 12 luni

Medie 41.08 USD  1.51%

Maxim 64 USD

Minim 26 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPTC Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

15 ratings

6

Cumpărare

6

Păstrare

3

Vânzare

Scor tehnic

By Trading Central

40.37 / 40.59Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

167 / 389 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre PTC Therapeutics Inc

PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).